, 12:211 | Cite as

Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis



Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) shows promise as a chemotherapeutic agent. However, many human cancer cells are resistant to killing by TRAIL. We have previously demonstrated that reovirus infection increases the susceptibility of human lung (H157) and breast (ZR75-1) cancer cell lines to TRAIL-induced apoptosis. We now show that reovirus also increases the susceptibility of human ovarian cancer cell lines (OVCAR3, PA-1 and SKOV-3) to TRAIL-induced apoptosis. Reovirus-induced increases in susceptibility of OVCAR3 cells to TRAIL require virus uncoating and involve increased activation of caspases 3 and 8. Reovirus infection results in the down-regulation of cFLIP (cellular FLICE inhibitory protein) in OVCAR3 cells. Down-regulation of cFLIP following treatment of OVCAR3 cells with antisense cFLIP oligonucleotides or PI3 kinase inhibition also increases the susceptibility of OVCAR3 cells to TRAIL-induced apoptosis. Finally, over-expression of cFLIP blocks reovirus-induced sensitization of OVCAR3 cells to TRAIL-induced apoptosis. The combination of reovirus and TRAIL thus represents a promising new therapeutic approach for the treatment of ovarian cancer.


Reovirus TRAIL cFLIP OVCAR3 Apoptosis 


  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31, 1CrossRefPubMedGoogle Scholar
  2. 2.
    Partridge EE, Barnes MN (1999) Epithelial ovarian cancer: Prevention, diagnosis, and treatment. CA Cancer J Clin 49:297–20CrossRefPubMedGoogle Scholar
  3. 3.
    Ashkenazi A, Dixit VM (1998) Death receptors: Signaling and modulation. Science 281:1305–308CrossRefPubMedGoogle Scholar
  4. 4.
    Hao C, Beguinot F, Condorelli G, et al (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162–170PubMedGoogle Scholar
  5. 5.
    Chang DW, Xing Z, Pan Y, et al (2002) c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21:3704–714CrossRefPubMedGoogle Scholar
  6. 6.
    Ashkenazi A, Pai RC, Fong S, et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Walczak H, Miller RE, Ariail K, et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–63CrossRefPubMedGoogle Scholar
  8. 8.
    Wiley SR, Schooley K, Smolak PJ, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–82CrossRefPubMedGoogle Scholar
  9. 9.
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–2690CrossRefPubMedGoogle Scholar
  10. 10.
    Bodmer JL, Holler N, Reynard S, et al (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2:241–43CrossRefPubMedGoogle Scholar
  11. 11.
    Kischkel FC, Hellbardt S, Behrmann I, et al (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579–588PubMedGoogle Scholar
  12. 12.
    Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM (1998) An induced proximity model for caspase-8 activation. J Biol Chem 273:2926–930CrossRefPubMedGoogle Scholar
  13. 13.
    Boatright KM, Renatus M, Scott FL, et al (2003) A unified model for apical caspase activation. Mol Cell 11:529–41CrossRefPubMedGoogle Scholar
  14. 14.
    Degli-Esposti MA, Smolak PJ, Walczak H, et al (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165–170CrossRefPubMedGoogle Scholar
  15. 15.
    Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813–20CrossRefPubMedGoogle Scholar
  16. 16.
    Marsters SA, Sheridan JP, Pitti RM, et al (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003–006CrossRefPubMedGoogle Scholar
  17. 17.
    Sheridan JP, Marsters SA, Pitti RM, et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–21CrossRefPubMedGoogle Scholar
  18. 18.
    Emery JG, McDonnell P, Burke MB, et al (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–4367CrossRefPubMedGoogle Scholar
  19. 19.
    Holen I, Croucher PI, Hamdy FC, Eaton CL (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619–623PubMedGoogle Scholar
  20. 20.
    Neville-Webbe HL, Cross NA, Eaton CL, et al (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86:269–79CrossRefPubMedGoogle Scholar
  21. 21.
    Shipman CM, Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912–16PubMedGoogle Scholar
  22. 22.
    Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y (1999) Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (review). Int J Oncol 15:793–02PubMedGoogle Scholar
  23. 23.
    Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM (2000) Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 35:603–07CrossRefPubMedGoogle Scholar
  24. 24.
    Grotzer MA, Eggert A, Zuzak TJ, et al (2000) Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19:4604–610CrossRefPubMedGoogle Scholar
  25. 25.
    Hu WH, Johnson H, Shu HB (2000) Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem 275:10838–0844CrossRefPubMedGoogle Scholar
  26. 26.
    Deng Y, Lin Y, Wu X (2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16:33–5CrossRefPubMedGoogle Scholar
  27. 27.
    Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21:2283–294CrossRefPubMedGoogle Scholar
  28. 28.
    Hinz S, Trauzold A, Boenicke L, et al (2000) Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19:5477–486CrossRefPubMedGoogle Scholar
  29. 29.
    Kim K, Fisher MJ, Xu SQ, el Deiry WS (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6:335–46PubMedGoogle Scholar
  30. 30.
    Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H (2002) Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 8:725–32PubMedGoogle Scholar
  31. 31.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S (2001) Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81:380–90CrossRefPubMedGoogle Scholar
  32. 32.
    Siervo-Sassi RR, Marrangoni AM, Feng X, et al (2003) Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190:61–2CrossRefPubMedGoogle Scholar
  33. 33.
    Lane D, Cartier A, L’Esperance S, Cote M, Rancourt C, Piche A (2004) Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol 93:594–04CrossRefPubMedGoogle Scholar
  34. 34.
    Vignati S, Codegoni A, Polato F, Broggini M (2002) Trail activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs. Eur J Cancer 38:177–83CrossRefPubMedGoogle Scholar
  35. 35.
    Tomek S, Horak P, Pribill I, et al (2004) Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94:107–14CrossRefPubMedGoogle Scholar
  36. 36.
    Horak P, Pils D, Kaider A, et al (2005) Perturbation of the tumor necrosis factor–related apoptosis-inducing ligand cascade in ovarian cancer: Overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 11:8585–591CrossRefPubMedGoogle Scholar
  37. 37.
    Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276:20633–0640CrossRefPubMedGoogle Scholar
  38. 38.
    Chang DW, Xing Z, Pan Y, et al (2002) c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21:3704–714CrossRefPubMedGoogle Scholar
  39. 39.
    Micheau O, Thome M, Schneider P, et al (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277:45162–5171CrossRefPubMedGoogle Scholar
  40. 40.
    Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS (2004) Activation of caspases-8 and -10 by FLIP(L). Biochem J 382:651–57CrossRefPubMedGoogle Scholar
  41. 41.
    Strong JE, Lee PW (1996) The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70:612–16PubMedGoogle Scholar
  42. 42.
    Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 17:3351–362CrossRefPubMedGoogle Scholar
  43. 43.
    Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282:1332–334CrossRefPubMedGoogle Scholar
  44. 44.
    Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62:1696–701PubMedGoogle Scholar
  45. 45.
    Alain T, Hirasawa K, Pon KJ, et al (2002) Reovirus therapy of lymphoid malignancies. Blood 100:4146–153CrossRefPubMedGoogle Scholar
  46. 46.
    Norman KL, Coffey MC, Hirasawa K, et al (2002) Reovirus oncolysis of human breast cancer. Hum Gene Ther 13:641–52CrossRefPubMedGoogle Scholar
  47. 47.
    Wilcox ME, Yang W, Senger D, et al (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93:903–12CrossRefPubMedGoogle Scholar
  48. 48.
    Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M (2004) Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 31:407–12PubMedGoogle Scholar
  49. 49.
    Tyler KL, Squier MK, Brown AL, et al (1996) Linkage between reovirus-induced apoptosis and inhibition of cellular DNA synthesis: Role of the S1 and M2 genes. J Virol 70:7984–991PubMedGoogle Scholar
  50. 50.
    Connolly JL, Dermody TS (2002) Virion disassembly is required for apoptosis induced by reovirus. J Virol 76:1632–641CrossRefPubMedGoogle Scholar
  51. 51.
    Okano H, Shiraki K, Inoue H, et al (2003) Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83:1033–043CrossRefPubMedGoogle Scholar
  52. 52.
    Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM (1999) FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 190:1679–688CrossRefPubMedGoogle Scholar
  53. 53.
    Tyler KL, Squier MK, Rodgers SE, et al (1995) Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol 69:6972–979PubMedGoogle Scholar
  54. 54.
    Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL (2001) Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 20:6910–919CrossRefPubMedGoogle Scholar
  55. 55.
    Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30:723–31CrossRefPubMedGoogle Scholar
  56. 56.
    Sturzenbecker LJ, Nibert M, Furlong D, Fields BN (1987) Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle. J Virol 61:2351–361PubMedGoogle Scholar
  57. 57.
    Bortul R, Tazzari PL, Cappellini A, et al (2003) Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 17:379–89CrossRefPubMedGoogle Scholar
  58. 58.
    Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M (2003) Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63: 1365–370PubMedGoogle Scholar
  59. 59.
    Ryu BK, Lee MG, Chi SG, Kim YW, Park JH (2001) Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194:15–9CrossRefPubMedGoogle Scholar
  60. 60.
    Jonsson G, Paulie S, Grandien A (2003) High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23:1213–218PubMedGoogle Scholar
  61. 61.
    Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–840PubMedGoogle Scholar
  62. 62.
    Brooks AD, Sayers TJ (2005) Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 54:499–05CrossRefPubMedGoogle Scholar
  63. 63.
    Van Valen F, Fulda S, Schafer KL, et al (2003) Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer 107:929–40CrossRefPubMedGoogle Scholar
  64. 64.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK (2005) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16:1125–138PubMedGoogle Scholar
  65. 65.
    El Zawahry A, Lu P, White SJ, Voelkel-Johnson C (2006) in vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 13:281–89CrossRefPubMedGoogle Scholar
  66. 66.
    Shishodia S, Aggarwal BB (2004) Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279:47148–7158CrossRefPubMedGoogle Scholar
  67. 67.
    Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG (2005) 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: An effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 105:1750–758CrossRefPubMedGoogle Scholar
  68. 68.
    Boehrer S, Nowak D, Puccetti E, et al (2006) Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk Res 30:597–05CrossRefPubMedGoogle Scholar
  69. 69.
    DeBiasi RL, Clarke P, Meintzer S, et al (2003) Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis. J Virol 77:8934–947CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  1. 1.Departments of NeurologyUniversity of Colorado Health Sciences CenterDenverUSA
  2. 2.Departments of Medicine, Microbiology and ImmunologyDenver Veterans Affairs Medical CenterDenverUSA

Personalised recommendations